Pharmaceutical Financial Analysts
Executive Summary
Biennial survey of investment community by Opinion Research Corp. of Princeton, N.J. indicates that financial analysts are having to cover more companies as size of health care industry grows. Opinion Research Senior VP Henry Dursin told a conference May 7 in Boston that the average number of companies followed by an analyst in the health care field is now up to 45 from 33 in 1979 and 30 ten years go. The analyst group covering the drug industry is showing more experience with the industry -- more than a third of the analysts surveyed had been following the industry for 10 years-plus. The average length covering the industry was 8 years.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.